Nomura Holdings’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $785K | Buy |
4,550
+1,707
| +60% | +$316K | ﹤0.01% | 1235 |
|
|
2025
Q4 | $567K | Sell |
2,843
-803,432
| -100% | -$146M | ﹤0.01% | 1495 |
|
|
2025
Q3 | $126M | Sell |
806,275
-762,994
| -49% | -$121M | 0.2% | 84 |
|
|
2025
Q2 | $238M | Buy |
1,569,269
+967,654
| +161% | +$129M | 0.5% | 46 |
|
|
2025
Q1 | $90.6M | Buy |
601,615
+293,815
| +95% | +$49.3M | 0.17% | 89 |
|
|
2024
Q4 | $56.8M | Buy |
+307,800
| New | +$59.3M | 0.08% | 137 |
|
|
2024
Q3 | – | Sell |
-6,500
| Closed | -$1.34M | – | 1606 |
|
|
2024
Q2 | $1.34M | Sell |
6,500
-3,763
| -37% | -$853K | ﹤0.01% | 1059 |
|
|
2024
Q1 | $2.78M | Buy |
10,263
+9,243
| +906% | +$2.21M | 0.01% | 809 |
|
|
2023
Q4 | $241K | Buy |
+1,020
| New | +$201K | ﹤0.01% | 1535 |
|
|
2022
Q2 | – | Sell |
-962
| Closed | -$278K | – | 1876 |
|
|
2022
Q1 | $278K | Buy |
962
+120
| +14% | +$37K | ﹤0.01% | 1468 |
|
|
2021
Q4 | $317K | Sell |
842
-597
| -41% | -$232K | ﹤0.01% | 1662 |
|
|
2021
Q3 | $600K | Buy |
1,439
+265
| +23% | +$110K | ﹤0.01% | 1325 |
|
|
2021
Q2 | $434K | Sell |
1,174
-5,576
| -83% | -$1.86M | ﹤0.01% | 1425 |
|
|
2021
Q1 | $1.96M | Buy |
+6,750
| New | +$1.88M | ﹤0.01% | 872 |
|
|
2020
Q2 | – | Sell |
-2,000
| Closed | -$253K | – | 1138 |
|
|
2020
Q1 | $253K | Buy |
+2,000
| New | +$300K | ﹤0.01% | 733 |
|
|
2017
Q3 | – | Sell |
-3,513
| Closed | -$347K | – | 1498 |
|
|
2017
Q2 | $347K | Sell |
3,513
-2,119
| -38% | -$195K | ﹤0.01% | 1308 |
|
|
2017
Q1 | $506K | Buy |
+5,632
| New | +$478K | ﹤0.01% | 916 |
|
|
2016
Q3 | – | Sell |
-39,242
| Closed | -$3.24M | – | 1212 |
|
|
2016
Q2 | $3.24M | Buy |
39,242
+29,741
| +313% | +$2.45M | 0.01% | 535 |
|
|
2016
Q1 | $715K | Buy |
+9,501
| New | +$703K | ﹤0.01% | 773 |
|
|
2015
Q3 | – | Sell |
-8,597
| Closed | -$594K | – | 1688 |
|
|
2015
Q2 | $594K | Buy |
+8,597
| New | +$636K | ﹤0.01% | 1198 |
|
|
2014
Q3 | – | Sell |
-8,473
| Closed | -$454K | – | 2804 |
|
|
2014
Q2 | $454K | Buy |
8,473
+4,781
| +129% | +$262K | ﹤0.01% | 1846 |
|
|
2014
Q1 | $224K | Sell |
3,692
-10,864
| -75% | -$633K | ﹤0.01% | 2270 |
|
|
2013
Q4 | $772K | Sell |
14,556
-177,539
| -92% | -$8.92M | ﹤0.01% | 1091 |
|
|
2013
Q3 | $8.88M | Buy |
192,095
+84,296
| +78% | +$3.87M | 0.05% | 291 |
|
|
2013
Q2 | $4.43M | Buy |
+107,799
| New | +$4.62M | 0.04% | 358 |
|
Other funds holding CRL
VCM
VPM
Nomura Holdings's CRL Position: Q1 2026 in Review
Nomura Holdings increased its Charles River Laboratories (CRL) stake by 60% in Q1 2026, buying an estimated $316K and bringing the position to 4,550 shares worth $785K. The position accounts for ﹤0.01% of the portfolio, ranked #1235.
Nomura Holdings first reported a position in CRL in Q2 2013 and has held it in 25 quarters since. The position peaked at $238M in Q2 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Nomura Holdings held 4,550 shares of Charles River Laboratories worth $785K as of Q1 2026.
- Nomura Holdings bought 1,707 Charles River Laboratories shares in Q1 2026, an estimated $316K.
- Charles River Laboratories made up ﹤0.01% of Nomura Holdings's portfolio in Q1 2026, its #1235 holding.
- Nomura Holdings first reported a position in Charles River Laboratories in Q2 2013 and has held it in 25 quarters since.
- Nomura Holdings's Charles River Laboratories position peaked at $238M in Q2 2025.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.